title: Effects of the Hypnotic Agent on Primary Graft Dysfunction After Liver Transplantation.
abstract: BACKGROUND
  Morbidity and mortality rates in orthotopic liver transplantation have decreased in the past few years. Risk factors related to severe postoperative complications, such as primary graft dysfunction, still need to be analyzed. We evaluated the influence of the hypnotic agent used during anesthesia on primary graft dysfunction.
  
  
  METHODS
  We performed a retrospective analysis of 419 consecutive patients who received a liver transplant between 2005 and 2013 in a single center. We analyzed the incidence of primary graft dysfunction (defined as alanine aminotransferase or aspartate aminotransferase levels higher than 1500 IU/L on the first 3 days after surgery) and if the hypnotic agent was associated with this event.
  
  
  RESULTS
  The incidence of primary graft dysfunction was 42.2% (114 patients), similar in both groups (propofol group, 89 patients, 43.2% and sevoflurane group, 25 patients, 39.1%). In the multivariate analysis, we did not find any relationship between the hypnotic agent (propofol or sevoflurane) and early graft dysfunction.
  
  
  CONCLUSIONS
  In our patients, we found no differences in the incidence of liver graft dysfunction according to the hypnotic used during transplantation. We can suggest that both drugs (sevoflurane and propofol) are equally safe in orthotopic liver transplantation.
authors.affiliation: Department of Anesthesiology and Intensive Care, Ramon y Cajal University Hospital, Madrid, Spain. Electronic address: gajate.luis@gmail.com.
authors.forename: L
authors.initials: L
authors.lastname: Gajate Martín
authors.affiliation: Department of Anesthesiology and Intensive Care, Ramon y Cajal University Hospital, Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: González
authors.affiliation: Department of Anesthesiology and Intensive Care, Ramon y Cajal University Hospital, Madrid, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Ruiz Torres
authors.affiliation: Department of Anesthesiology and Intensive Care, Ramon y Cajal University Hospital, Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Fernández Martín
authors.affiliation: Department of Anesthesiology and Intensive Care, Ramon y Cajal University Hospital, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Martín Grande
authors.affiliation: Department of Anesthesiology and Intensive Care, Ramon y Cajal University Hospital, Madrid, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Elías Martín
authors.affiliation: Department of Anesthesiology and Intensive Care, Ramon y Cajal University Hospital, Madrid, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Parise Roux
authors.affiliation: Department of Clinical Biochemistry, Ramon y Cajal University Hospital, Madrid, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Del Rey Sánchez
mesh_terms: D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000758:Anesthesia / Q000379:methods*; D001219:Aspartate Aminotransferases / Q000097:blood; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage* / Q000009:adverse effects; D015994:Incidence; D016031:Liver Transplantation; D008297:Male; D008738:Methyl Ethers / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D015999:Multivariate Analysis; D055031:Primary Graft Dysfunction / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D015742:Propofol / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D012307:Risk Factors; D000077149:Sevoflurane; D013997:Time Factors
chemical_list: D006993:Hypnotics and Sedatives; D008738:Methyl Ethers; D000077149:Sevoflurane; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D015742:Propofol